Genzyme

Isis Pharmaceuticals and partner Genzyme announced this week that the US Food and Drug Administration has approved their antisense drug Kynamro, known generically as mipomersen, for the treatment of homozygous familial hypercholesterolemia.

This article has been updated with additional details about the strategic alliance.

Isis Pharmaceuticals this week said that it stands to receive a $1.1 million payment tied to Alnylam Pharmaceuticals' strategic alliance with Genyzme.

With Positive Survival Data, Genentech Crossing over EMILIA Patients on Lapatinib/Capecitabine Combo to T-DM1

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Genzyme and Veracyte today announced a co-marketing deal covering Veracyte's thyroid diagnostic tool.

Specifically, the companies are seeking clearance to commercialize the 200 mg weekly dose of the drug for the treatment of homozygous and severe heterozygous familial hypercholesterolemia.

Following a positive recommendation from the EMA committee, the European Commission is expected to issue a decision in September regarding marketing Tarceva as a first-line treatment for EGFR-mutation-positive NSCLC.

LabCorp plans to integrate Genzyme Genetics' reimbursement and IT teams at the Westborough, Mass., facility into its own operations.

Paired Ends

Premium

Richard Green, Marc Beer

LabCorp completed the $925 million deal around three months after it was initially announced.

Pages

An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.

An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.

Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.